To date, autoantibodies targeting GAD65 have been associated with neurological autoimmune-related syndromes in adults, including cerebellar ataxia, stiff-person syndrome, and drug-resistant TLE [1, 2]. Here, GAD2 is linked to stiff-person syndrome.